3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Small Cell Lung Carcinoma
10
Carcinoma, Non-Small-Cell Lung
10
Carcinoma, Hepatocellular
8
Lung Neoplasms
6
Colorectal Neoplasms
6
Neoplasms
5
Prostatic Neoplasms
4
Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Solid Tumors
2
Small Cell Lung Cancer Extensive Stage
2
Sarcoma, Alveolar Soft Part
2
Sarcoma
2
Ovarian Neoplasms
2
Mesothelioma, Malignant
2
Melanoma
2
Liver Neoplasms
2
Extensive Stage Lung Small Cell Carcinoma
2
Carcinoma, Renal Cell
2
Carcinoma
2
Wilms Tumor
1
Vulvar Neoplasms
1
Vaccinia
1
Sarcoma, Clear Cell
1
Rhabdomyosarcoma
1
Papillary renal cell carcinoma, sporadic
1
PIK3CA-Mutated Cancers
1
Osteosarcoma
1
Interventions
atezolizumab
2
Etoposide
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Small Cell Lung Cancer Extensive Stage
×
atezolizumab
×
30 days
×
Clear all
NCT05703971
2026-06-03
Acclaim-3
Genprex, Inc.
Phase 1/2
Recruiting
62 enrolled
NCT07227597
2026-05-28
MK-6070-003
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
170 enrolled